News >

Targeting Acquired Resistance Leads EGFR+ NSCLC Research Efforts

Nichole Tucker
Published: Monday, Jul 08, 2019

Heather A. Wakelee, MD

Heather A. Wakelee, MD
Combination strategies with osimertinib (Tagrisso) are in the midst of investigations in an effort to target patients with EGFR-mutant non–small cell lung cancer (NSCLC) with acquired resistance mechanisms, explained Heather A. Wakelee, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication